Clinical trials: Rosuvastatin
Healthy Volunteers
A Study of PF-06651600 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
A phase 1, 2-period, fixed-sequence, multiple-dose, open-label study of the effect of PF-06651600 on Rosuvastatin pharmacokinetics in healthy participants.
- Trial name
- NCT04092595
- Testing
- PF-06651600, Rosuvastatin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia
Introduction: The COVID-19 pandemic is characterized by significant morbidity and mortality. Treatments have been administered to patients with COVID-19 in order to control viral infection, among them: Hydroxychloroquine (HCQ)…
- Trial name
- NCT04359095
- Testing
- Emtricitabine/tenofovir, Colchicine Pill, Rosuvastatin
- Where
- 6 sites in Colombia
- Volunteers
- 650 people
- Sponsor
- Universidad Nacional de Colombia
HIV Infection
Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial
This study will determine whether 36 months of daily atorvastatin or rosuvastatin have equivalent effects in reduction of immune activation, inflammation and immune aging, when given as adjunct therapy among patients receiving…
- Trial name
- STAR (NCT03037372)
- Testing
- ART, Atorvastatin, ART, Rosuvastatin, ART, No statin
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Makerere University
Pharmacokinetics
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
The cholesterol-lowering drug rosuvastatin is a substrate of the breast cancer resistance protein (BCRP). BCRP is an efflux transporter expressed e.g. in the small intestine.
- Trial name
- KF2019#1 (NCT05373277)
- Testing
- Ticagrelor, Rosuvastatin
- Where
- Finland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Type 2 Diabetes, Diabetic Dyslipidemia
Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients
Type 2 diabetes (T2D), because of impaired glucose regulation and consequent hyperglycemia, promotes the development of coronary heart disease.
- Trial name
- NCT00854503
- Testing
- Simvastatin, Rosuvastatin
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Rome Tor Vergata
Autoimmune Diseases, Inflammatory Diseases
Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin
The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the systemic exposure of rosuvastatin in healthy participants.
- Trial name
- NCT03044873
- Testing
- BMS-986165, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke
Effects of Short-term Intensive Statin Therapy on Lipid Levels
Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques.
- Trial name
- NCT07344610
- Testing
- statin
- Where
- China
- Volunteers
- 800 people
- Sponsor
- General Hospital of Shenyang Military Region
Healthy
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
The objective of this trial is to assess the effect of BI 3000202 on the pharmacokinetics of rosuvastatin and digoxin given as a cocktail.
- Trial name
- NCT07215260
- Testing
- BI 3000202, Rosuvastatin, Digoxin
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.
- Trial name
- NCT07088913
- Testing
- Capivasertib, Rosuvastatin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Erectile Dysfunction Due to Arterial Disease, Atheroscleroses
TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men
Aim. To study the effect of different intensities of statin therapy on androgen status and erectile function in men aged 40-65 years with high and very high cardiovascular risk.
- Conditions
- Erectile Dysfunction Due to Arterial Disease, Atheroscleroses, Erectile Disfunction, Endothelial Dysfunction
- Trial name
- NCT07460960
- Testing
- Pitavastatin 1-4 mg daily, Rosuvastatin 20-40 mg daily
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Lomonosov Moscow State University Medical Research and Educational Center
Healthy
A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood
Effects of multiple rising doses of BI 1839100 on safety, tolerability, pharmacokinetics and the effect of high-fat meal on pharmacokinetics of BI 1839100 will be assessed as well as assessing potential drug-drug interactions.
- Trial name
- NCT05738291
- Testing
- BI 1839100, midazolam, digoxin
- Where
- Netherlands
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke
This study is an investigator-initiated, multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial (PROBE design) that includes patients with moderate or severe symptomatic intracranial large vessel…
- Trial name
- CAPTAIN (NCT06696820)
- Testing
- PCSK9 inhibitors combined with atorvastatin/rosuvastatin, Atorvastatin/Rosuvastatin
- Where
- 2 sites in China
- Volunteers
- 429 people
- Sponsor
- Xiang Luo
Hypercholesterolemia, Type 2 Diabetes
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments
The study is being conducted to compare the effect of standard treatment (target LDL-C level: <120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: <70 mg/dL) in the prevention of major adverse…
- Conditions
- Hypercholesterolemia, Type 2 Diabetes, Hypertension
- Trial name
- POSITIVE (NCT01173939)
- Testing
- Pravastatin, Rosuvastatin
- Where
- 317 sites in Japan
- Volunteers
- 10,000 people
- Sponsor
- Positive Trial Group
Head Injury
Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury
The purpose of this study is to determine whether rosuvastatin could alter the immunological response after head injury by modulating TNF-alpha,IL6,IL-1.
- Trial name
- NCT00990028
- Testing
- Rosuvastatin
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin therapy with or without other lipid modifying therapy in comparison with…
- Trial name
- NCT02107898
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 32 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Sanofi
Hypercholesterolemia, Dyslipidemias
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
- Trial name
- PIVOTAL (NCT07083206)
- Where
- South Korea
- Volunteers
- 4,500 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Stroke
Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects
This is a single-centre phase I study to assess the Drug-Drug Interaction potential of MLC1501 with a cocktail of drugs acting as sensitive clinical probe substrates of Cytochrome P450 isoenzymes and Transporters in healthy…
- Trial name
- NCT04233437
- Testing
- MLC1501, CYP Cocktail, Transporter Cocktail
- Where
- Australia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Moleac Pte Ltd.
Randomized Controlled Trials
Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography
The study is a prospective, open-label, randomized, single-center study involving patients with intermediate coronary lesions (50%-70% diameter stenosis) and who have elevated LDL-C values (LDL-C≥100 mg/dL) despite stable statin…
- Trial name
- NCT04851769
- Testing
- PCSK9 inhibitor plus statin, standard statin therapy, Coronary imaging follow-up
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Anzhen Hospital
Atherosclerotic Cardiovascular Disease
Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial
Although the clinical efficacy of LDL-cholesterol lowering therapy has been proven with strong evidences and emphasized, there are also growing concerns that intensive lipid-lowering therapy would be related to increased risk of…
- Trial name
- NCT04626973
- Testing
- Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin), Statin monotherapy (rosuvastatin or atorvastatin)
- Where
- South Korea
- Volunteers
- 3,048 people
- Sponsor
- Yonsei University
Statin Adverse Reaction
Quality of Life in Patients With Statin-Associated Myopathy
The proposed study will focus on possible effects of statins on muscle strength and why they become tired more easily, quality of life, and measurements to understand why muscles are not able to fully utilize fats.
- Trial name
- NCT00850460
- Testing
- Statins
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rockefeller University